Teva Jumps as New CEO Jeremy Levin Set to Give Guidance Update
Teva Pharmaceutical Industries Ltd. (TEVA) rose the most in almost two months before new Chief Executive Officer Jeremy Levin gives an update on financial guidance.
The stock of the world’s largest generic drugmaker jumped the most since April 1, adding 2.4 percent to 153 shekels at 2:36 p.m. in Tel Aviv.
To contact the reporter on this story: David Wainer in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org